These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30671792)

  • 1. Lymphocyte to Monocyte Ratio Predicts Resectability and Early Recurrence of Bismuth-Corlette Type IV Hilar Cholangiocarcinoma.
    Peng D; Lu J; Hu H; Li B; Ye X; Cheng N
    J Gastrointest Surg; 2020 Feb; 24(2):330-340. PubMed ID: 30671792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?
    Wang JK; Hu HJ; Shrestha A; Ma WJ; Yang Q; Liu F; Cheng NS; Li FY
    Oncotarget; 2017 Jul; 8(28):45335-45344. PubMed ID: 28484084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of lymphovascular invasion in Bismuth-Corlette type IV hilar cholangiocarcinoma.
    Li B; Xiong XZ; Zhou Y; Wu SJ; You Z; Lu J; Cheng NS
    World J Gastroenterol; 2017 Sep; 23(36):6685-6693. PubMed ID: 29085213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between serum MMP-9 level and prognosis after radical resection for Hilar cholangiocarcinoma patients.
    Li O; Yi W; Yang P; Guo C; Peng C
    Acta Cir Bras; 2019 Apr; 34(4):e201900409. PubMed ID: 31038586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma.
    Hu HJ; Jin YW; Zhou RX; Ma WJ; Yang Q; Wang JK; Liu F; Cheng NS; Li FY
    J Gastrointest Surg; 2019 Mar; 23(3):510-517. PubMed ID: 30076591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma.
    Cai WK; Lin JJ; He GH; Wang H; Lu JH; Yang GS
    Int J Clin Exp Pathol; 2014; 7(11):7890-8. PubMed ID: 25550829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of early recurrence after R0 resection of hilar cholangiocarcinoma: A single institution experience in China.
    Hu HJ; Jin YW; Shrestha A; Ma WJ; Wang JK; Liu F; Zhu YY; Zhou RX; Regmi P; Cheng NS; Li FY
    Cancer Med; 2019 Apr; 8(4):1567-1575. PubMed ID: 30868740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated?
    Lu J; Li B; Li FY; Ye H; Xiong XZ; Cheng NS
    Eur J Surg Oncol; 2019 Nov; 45(11):2173-2179. PubMed ID: 31208772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of Biliary Confluence Pattern for Bismuth-Corlette Type IV Hilar Cholangiocarcinoma Applied to Hemihepatectomy.
    Ji GW; Zhu FP; Wang K; Jiao CY; Shao ZC; Li XC
    J Gastrointest Surg; 2017 Apr; 21(4):666-675. PubMed ID: 28168674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
    Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
    World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of clinical outcomes of advanced hilar cholangiocarcinoma.
    Chen KJ; Yang FC; Qin YS; Jin J; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):155-162. PubMed ID: 29636302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical resection for hilar cholangiocarcinoma: experience improves resectability.
    Cannon RM; Brock G; Buell JF
    HPB (Oxford); 2012 Feb; 14(2):142-9. PubMed ID: 22221577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.
    Chen P; Li B; Zhu Y; Chen W; Liu X; Li M; Duan X; Yi B; Wang J; Liu C; Luo X; Li X; Li J; Liang L; Yin X; Wang H; Jiang X
    Oncotarget; 2016 Jun; 7(24):37319-37330. PubMed ID: 27144432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized preoperative planning using three-dimensional modeling for Bismuth and Corlette type III hilar cholangiocarcinoma.
    Zeng N; Tao H; Fang C; Fan Y; Xiang N; Yang J; Zhu W; Liu J; Guan T; Fang C; Xiang F
    World J Surg Oncol; 2016 Feb; 14(1):44. PubMed ID: 26911245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis of patients with stage T2a and T2b perihilar cholangiocarcinoma treated with radical resection.
    Zhao J; Zhang W; Zhang J; Zhang Y; Ma WJ; Liu SY; Li FY; Song B
    BMC Cancer; 2020 Sep; 20(1):849. PubMed ID: 32883228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal ultrasonography combined with percutaneous transhepatic cholangioscopy for the preoperative evaluation of longitudinal tumor extent in hilar cholangiocarcinoma.
    Kim HM; Park JY; Kim KS; Park MS; Kim MJ; Park YN; Bang S; Song SY; Chung JB; Park SW
    J Gastroenterol Hepatol; 2010 Feb; 25(2):286-92. PubMed ID: 19780880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.
    Lin ZX; Ruan DY; Li Y; Wu DH; Ma XK; Chen J; Chen ZH; Li X; Wang TT; Lin Q; Wen JY; Wu XY
    World J Gastroenterol; 2015 Oct; 21(38):10898-906. PubMed ID: 26478681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified Jarnagin-Blumgart classification better predicts survival for resectable hilar cholangiocarcinoma.
    Ding G; Yang Y; Cao L; Chen W; Wu Z; Jiang G
    World J Surg Oncol; 2015 Mar; 13():99. PubMed ID: 25889726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.
    Zhang XF; Beal EW; Chakedis J; Chen Q; Lv Y; Ethun CG; Salem A; Weber SM; Tran T; Poultsides G; Son AY; Hatzaras I; Jin L; Fields RC; Buettner S; Scoggins C; Martin RCG; Isom CA; Idrees K; Mogal HD; Shen P; Maithel SK; Schmidt CR; Pawlik TM
    World J Surg; 2018 Sep; 42(9):2919-2929. PubMed ID: 29404753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
    Zhou C; Duan D; Liu S
    Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.